Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.

Desai R, Parashar UD, Lopman B, de Oliveira LH, Clark AD, Sanderson CF, Tate JE, Matus CR, Andrus JK, Patel MM.

Clin Infect Dis. 2012 May;54(10):1397-405. doi: 10.1093/cid/cis191. Epub 2012 Mar 19.

PMID:
22431803
2.

Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.

Patel MM, Clark AD, Glass RI, Greenberg H, Tate J, Santosham M, Sanderson CF, Steele D, Cortese M, Parashar UD.

Vaccine. 2009 May 14;27(22):2916-22. doi: 10.1016/j.vaccine.2009.03.016. Epub 2009 Mar 25.

PMID:
19428901
3.

Potential intussusception risk versus benefits of rotavirus vaccination in the United States.

Desai R, Cortese MM, Meltzer MI, Shankar M, Tate JE, Yen C, Patel MM, Parashar UD.

Pediatr Infect Dis J. 2013 Jan;32(1):1-7. doi: 10.1097/INF.0b013e318270362c.

4.

Rotavirus vaccination in Brazil: effectiveness and health impact seven years post-introduction.

Linhares AC, Justino MC.

Expert Rev Vaccines. 2014 Jan;13(1):43-57. doi: 10.1586/14760584.2014.861746. Epub 2013 Dec 4. Review.

PMID:
24308577
5.

Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil.

Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, Bautista Márquez A, Flannery B, Esparza-Aguilar M, Montenegro Renoiner EI, Luna-Cruz ME, Sato HK, Hernández-Hernández Ldel C, Toledo-Cortina G, Cerón-Rodríguez M, Osnaya-Romero N, Martínez-Alcazar M, Aguinaga-Villasenor RG, Plascencia-Hernández A, Fojaco-González F, Hernández-Peredo Rezk G, Gutierrez-Ramírez SF, Dorame-Castillo R, Tinajero-Pizano R, Mercado-Villegas B, Barbosa MR, Maluf EM, Ferreira LB, de Carvalho FM, dos Santos AR, Cesar ED, de Oliveira ME, Silva CL, de Los Angeles Cortes M, Ruiz Matus C, Tate J, Gargiullo P, Parashar UD.

N Engl J Med. 2011 Jun 16;364(24):2283-92. doi: 10.1056/NEJMoa1012952.

6.

Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis.

Patel MM, Clark AD, Sanderson CF, Tate J, Parashar UD.

PLoS Med. 2012;9(10):e1001330. doi: 10.1371/journal.pmed.1001330. Epub 2012 Oct 23.

7.

Evaluating the potential risks and benefits of infant rotavirus vaccination in England.

Clark A, Jit M, Andrews N, Atchison C, Edmunds WJ, Sanderson C.

Vaccine. 2014 Jun 17;32(29):3604-10. doi: 10.1016/j.vaccine.2014.04.082. Epub 2014 May 9.

PMID:
24814524
8.

Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009.

Yen C, Tate JE, Steiner CA, Cortese MM, Patel MM, Parashar UD.

J Infect Dis. 2012 Jul 1;206(1):41-8. doi: 10.1093/infdis/jis314. Epub 2012 Apr 26.

PMID:
22539812
9.

Rotavirus vaccines and vaccination in Latin America.

Linhares AC, Bresee JS.

Rev Panam Salud Publica. 2000 Nov;8(5):305-31. Review.

PMID:
11190969
10.

Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.

Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R.

Vaccine. 2013 Oct 1;31(42):4902-10. doi: 10.1016/j.vaccine.2013.07.014. Epub 2013 Jul 16.

PMID:
23871824
11.

Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008521. doi: 10.1002/14651858.CD008521.pub3. Review.

PMID:
23152260
12.

Research priorities regarding rotavirus vaccine and intussusception: a meeting summary.

Tate JE, Steele AD, Bines JE, Zuber PL, Parashar UD.

Vaccine. 2012 Apr 27;30 Suppl 1:A179-84. doi: 10.1016/j.vaccine.2011.08.110.

PMID:
22520129
13.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138
14.

Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico.

Velázquez FR, Colindres RE, Grajales C, Hernández MT, Mercadillo MG, Torres FJ, Cervantes-Apolinar M, DeAntonio-Suarez R, Ortega-Barria E, Blum M, Breuer T, Verstraeten T.

Pediatr Infect Dis J. 2012 Jul;31(7):736-44. doi: 10.1097/INF.0b013e318253add3.

PMID:
22695189
15.
16.

Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York state.

Chang HG, Smith PF, Ackelsberg J, Morse DL, Glass RI.

Pediatrics. 2001 Jul;108(1):54-60.

PMID:
11433054
17.
18.

Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.

Ledent E, Lieftucht A, Buyse H, Sugiyama K, Mckenna M, Holl K.

Drug Saf. 2016 Mar;39(3):219-30. doi: 10.1007/s40264-015-0376-7.

19.

Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries.

Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T.

Rev Panam Salud Publica. 2007 Apr;21(4):205-16.

PMID:
17612464
20.

Workshop on intussusception in African countries--meeting report.

Steele AD, Patel M, Cunliffe NA, Bresee JS, Borgstein E, Parashar UD.

Vaccine. 2012 Apr 27;30 Suppl 1:A185-9. doi: 10.1016/j.vaccine.2011.10.004.

PMID:
22520130

Supplemental Content

Support Center